Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy
Tasneem Z. Naqvi, MD, MRCP, FACCa,
Rishi K. Goel, BS, BA, /a,
James S. Forrester, MD, FACCa and
Robert J. Siegel, MD, FACCa
a Cardiac Noninvasive Laboratory, Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California, USA

View larger version (17K):
[in a new window]
|
Figure 1 Changes in LV WMSI, ESD, mitral inflow E-wave, LV mass (g/ml) and SIED in patients whose follow-up LVEF was >40% (group 1, solid black bars) versus patients whose follow-up LVEF was <40% (group 2, white bars) are shown. * = p < 0.05 versus group 1. EF = ejection fraction; ESD = end-systolic diameter; LV = left ventricular; SIED = end-diastolic sphericity index; WMSI = wall motion score index.
|
|

View larger version (28K):
[in a new window]
|
Figure 2 Left ventricular ejection fraction at baseline, in response to dobutamine and on follow-up in patients with LVEF >40% (left panel) and with LVEF <40% (right panel) on follow-up. Horizontal bars indicate the mean value of LVEF in each group. LVEF = left ventricular ejection fraction.
|
|

View larger version (16K):
[in a new window]
|
Figure 3 Linear regression analysis showing correlation between LVEF on dobutamine and LVEF on follow-up. LVEF = left ventricular ejection fraction. y = 10.8108 + 1.08*x; adjusted r2 = 0.68.
|
|
|